title: PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro.
abstract: BACKGROUND
  As a novel molecular markerof non-small cell lung cancer (NSCLC), PRDI-BF1 and RIZ homology domain containing protein 14 (PRDM14) is over-expressed in NSCLC tumor tissues. Extracellular matrix degradation mediated by the balance between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) is one of the most important mechanism in lung cancer metastasis. This study aimed to determine if PRDM14 promoted the migration of NSCLC cells through extracellular matrix degradation mediated by change of MMP/TIMP expression.
  
  
  METHODS
  The expression of PRDM14 was down-regulated in human cell line A 549 after transfection with lentiviral vector-mediated short-hairpin ribonucleic acids (shRNAs) which targeted the PRDM14 promoter. Cellular migration of shRNA-infected cells was detected by a scratch wound healing assay and transwell cell migration assay. Expression levels of MMP1, MMP2, TIMP1, and TIMP2 were measured by quantitative real-time polymerase chain reaction (RT-PCR).
  
  
  RESULTS
  Migration of PRDM14-shRNA-infected cells was significantly inhibited relative to control cells as measured by the scratch wound healing (P < 0.05) and transwell cell migration assays (P < 0.01). The expression of MMP1 in A549 cells infected by PRDM14-shRNA was down-regulated significantly (P < 0.01), whereas the expression of TIMP1 and TIMP2 was up-regulated significantly (P < 0.01).
  
  
  CONCLUSIONS
  PRDM14 accelerates A549 cells migration in vitro through extracellular matrix degradation. PRDM14 is considered as a potential therapeutic target in metastatic NSCLC.
authors: Hong-Xia
authors: HX
authors: Bi
authors: Han-Bing
authors: HB
authors: Shi
authors: Department of Pathology, Program in Molecular and Translational Medicine, School of Medicine, Huzhou University, Huzhou, Zhejiang 313000, China.
authors: Ting
authors: T
authors: Zhang
authors: Ge
authors: G
authors: Cui
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics / Q000502:physiology; D004268:DNA-Binding Proteins; D005109:Extracellular Matrix / Q000378:metabolism*; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D009362:Neoplasm Metastasis / Q000235:genetics; D016601:RNA-Binding Proteins; D012097:Repressor Proteins / Q000378:metabolism*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism; D014157:Transcription Factors
chemical_list: D004268:DNA-Binding Proteins; C524724:PRDM14 protein, human; D016601:RNA-Binding Proteins; D012097:Repressor Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; D014157:Transcription Factors; D019716:Tissue Inhibitor of Metalloproteinase-2; D020778:Matrix Metalloproteinase 2; D020781:Matrix Metalloproteinase 1
references: Anticancer Res. 2011 Nov;31(11):4031-8
references: 22110238
references: Chin Med J (Engl). 2011 Aug;124(15):2279-83
references: 21933557
references: Int J Cancer. 2009 Jan 1;124(1):95-102
references: 18844214
references: Nature. 2010 Nov 11;468(7321):316-20
references: 20953172
references: Nat Struct Mol Biol. 2011 Feb;18(2):120-7
references: 21183938
references: Genes Chromosomes Cancer. 2005 Nov;44(3):265-70
references: 16015645
references: J Natl Compr Canc Netw. 2010 Jul;8(7):740-801
references: 20679538
references: Histol Histopathol. 2000 Jan;15(1):109-17
references: 10668202
references: Dev Biol. 2007 Jun 1;306(1):112-20
references: 17428461
references: Neoplasia. 2005 Jun;7(6):556-62
references: 16036106
references: Cancer Res. 2007 Oct 15;67(20):9649-57
references: 17942894
references: Chin Med J (Engl). 2013;126(9):1683-8
references: 23652051
references: Cancer Res. 2011 Mar 1;71(5):1989-98
references: 21363926
references: Am J Pathol. 2002 Jun;160(6):2181-90
references: 12057921
references: Biochem Biophys Res Commun. 2008 Mar 21;367(4):899-905
references: 18194669
references: Cancer Biol Ther. 2011 Mar 15;11(6):584-91
references: 21278488
references: Oncogene. 2011 Jun 23;30(25):2859-73
references: 21339739
references: Haematologica. 2006 Apr;91(4):467-74
references: 16585013
references: Mol Biotechnol. 2007 Jul;36(3):184-204
references: 17873406
references: PLoS One. 2008;3(11):e3823
references: 19043588
references: Int J Cancer. 2003 Aug 20;106(2):244-51
references: 12800201
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Cell. 2012 Aug 31;150(5):948-60
references: 22939622
references: Chin Med J (Engl). 2005 Jan 5;118(1):69-72
references: 15642229
references: Biomark Cancer. 2011 Jun 07;3:31-40
references: 24179389
references: Cancer Biol Ther. 2011 May 1;11(9):801-11
references: 21383546
references: Clin Cancer Res. 2007 Aug 15;13(16):4786-94
references: 17699856
references: Oncogene. 2010 Jun 24;29(25):3715-22
references: 20418914
references: Cancer Biol Ther. 2010 Dec 1;10(11):1079-80
references: 21088497
references: PLoS One. 2012;7(5):e38175
references: 22675446
references: J Immunol. 2006 May 15;176(10):6211-8
references: 16670331
references: Zhongguo Fei Ai Za Zhi. 2010 Sep;13(9):867-72
references: 20840815
references: J Med Genet. 2002 Sep;39(9):644-55
references: 12205107
references: J Histochem Cytochem. 2003 May;51(5):567-74
references: 12704204